Venetoclax, an inhibitor of BCL-2, has been approved for combination with azacitidine or decitabine or low-dose cytarabine for the treatment of AML patients aged 75 years and above who are not suitable for intensive chemotherapy [32]. The gene discussed is BCL2; the disease is acute myeloid leukemia.